Exclusive Summary

• - Large patient pool: ~537 million adults with diabetes globally (>90% T2D), with rapid SGLT2 uptake driving fixed-dose combo demand.
• - Right timing: EU/Canada and most emerging markets are off-patent and open now; US FDC protection largely to 2025–2026, allowing pre-launch distribution setup.
• - Strong clinical value: Aligned with ADA/EASD 2024, delivering cardio-renal benefits and once-daily adherence; 2.5/1000, 5/1000, 10/1000 mg strengths enable tailored titration.
• - Manageable competition: Fewer true competitors in XR FDC versus mono or IR combos due to higher technical/BE barriers; 2.5/1000 mg offers differentiation in many markets.
• - Quality and cost: US-FDA GMP supports registrations and tenders; Chinese VBP scale enables 50–80% discounts vs originator for fast-volume distribution deals.